Prices are updated after-hours


Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date

entities : Cara therapeutics, inc.    crawled time : 12:01    save search

Cara Therapeutics Submits New Drug Application to U.S. Food and Drug Administration for KORSUVA™ Injection in Hemodialysis Patients with Moderate-to-Severe Pruritus
Published: 2020-12-28 (Crawled : 12:01) - globenewswire.com
CARA | $0.6816 -1.22% -1.23% 350K twitter stocktwits trandingview |
Health Technology
| | O: 1.91% H: 5.81% C: -1.88%

drug injection food hemodialysis new drug application
Cara Therapeutics Completes Full Enrollment in KARE Phase 2 Trial of Oral KORSUVA™ in Atopic Dermatitis Patients with Moderate-to-Severe Pruritus
Published: 2020-12-02 (Crawled : 12:01) - globenewswire.com
CARA | $0.6816 -1.22% -1.23% 350K twitter stocktwits trandingview |
Health Technology
| | O: 0.2% H: 2.31% C: 1.22%

dermatitis trial phase 2 atopic dermatitis enroll
Gainers vs Losers
67% 33%

Top 10 Gainers

Your saved searches
Save your searches and get alerts when important news are released.